The M3P Effect: Accelerating Catastrophic Phase Accrual Cliffs in Q4

How the Medicare Prescription Payment Plan artificially inflates Q3 and Q4 discount liabilities by increasing patient adherence and changing the velocity of OOP cap realization.

Christopher Biddle

Chief Regulatory Officer

The implementation of the Medicare Prescription Payment Plan (M3P) fundamentally alters the cash flow and liability models for highly specialized Part D portfolios. By essentially functioning as an interest-free loan that smooths out-of-pocket (OOP) costs over the calendar year, the mechanism removes traditional abandonment barriers associated with high-cost therapies in January and February.

While visually appealing for patient advocacy, this dynamic creates a severe, often unmodeled "Accrual Cliff" for manufacturers in the third and fourth quarters.

The Velocity of the OOP Cap

Under the 2025 benefit design, the OOP threshold is hard-capped at $2,000. Historically, for a drug costing $10,000 per month, a patient would hit the catastrophic phase in January. The manufacturer would instantly assume the 20% discount liability for the remainder of the year.

However, if that same patient opts into the M3P, their $2,000 obligation is spread out.

"Even though the patient is paying the $2,000 over 12 months, the statutory mechanism triggering the Catastrophic Phase remains tied to incurred costs at the point of sale, not the payment schedule of the patient."

Statutory Interpretation Error

A common modeling mistake is assuming manufacturer liability delays alongside the patient's payment plan. This is false. The manufacturer is liable for the 20% catastrophic discount immediately upon the patient's first dispense clearing the $2,000 threshold, regardless of M3P participation.

Adherence as a Liability Multiplier

The real financial danger isn't the timing of the catastrophic phase for existing patients—it's the retention of marginal patients.

Pre-IRA (Abandonment): A patient faces a $3,000 initial bill in January, abandons therapy, and the manufacturer incurs $0 in ongoing discount liability.
Post-IRA (M3P Retention): The patient agrees to a ~$166/month payment plan, stays on therapy all 12 months, and the manufacturer incurs a rigid 20% liability on $120,000 of gross sales ($24,000).

Q4 Accrual Miss

If your Gross-To-Net (GTN) models rely on historical 2021-2023 abandonment rates for specialty therapies, your Q4 catastrophic discount liabilities are likely under-accrued by 15% to 35%. When TPA invoices arrive in November, the sudden true-up will severely impact reported net revenue.

Defining High Risk

"High Risk" classification in KugelOne Intelligence Briefs designates regulatory mechanisms that possess two distinct characteristics:

Information Asymmetry: The interpretation of the statute is heavily contested or complex, leading to divergent modeling approaches across the industry.
Severe Financial Impact: A failure mode (or unmodeled variable) results in a non-linear financial penalty, typically an aggregate shift in discount rate (e.g., from 1% phase-in to a full 10% Initial Coverage liability) or a statutory penalty (e.g., the 25% surcharge for late MPP invoice payments).

Recommended Action

Manufacturers must immediately decouple historical adherence curves from 2025/2026 GTN forecasts. Update liability algorithms to assume a 100% adherence rate for the first three months of any patient opting into M3P, as the smoothed payments dramatically reduce early-stage drop-off.